The Role of the Renin-Angiotensin System in Vascular Health. Use of ACE Inhibition to Improve Vascular Function

Heart Disease

Volumn 2, Issue 5, 2000, Pages 380-383

  Izzo Jr , Joseph L ^a  

^a MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERIOSCLEROSIS; CARDIOVASCULAR FUNCTION; DRUG EFFECT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; CARDIOVASCULAR PHYSIOLOGY; ENDOTHELIUM, VASCULAR; HUMAN; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; SUPPORT, NON-U.S. GOV'T;

EID: 0034280367     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pepine CJ. The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. Am J Cardiol 1998; 82(Suppl 10A):23S-27S.
2. Harris LM, Faggioli GL, Shah R, et al. Vascular reactivity in patients with peripheral vascular disease. Am J Cardiol 1995;76:207-212.
3. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
4. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993;21:1145-1151.
5. Nussbacher A, Gerstenblith G, O'Connor F, et al. Hemodynamic effects of unloading the old heart. Am J Physiol 1999;277:H1863-H1871.
6. Izzo JL Jr, Levy D, Block HR. Importance of systolic hypertension in older Americans. Hypertension 2000;35:1021-1024.
7. 6A. Fleg JL. Aging and systemic hemodynamics. Hypertension Primer 1993;B11: 82-85.
8. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age in 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
9. Franklin SS, Khan ST, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999;100: 354-360.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265: 3255-3264.
11. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
12. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942.
13. Dzau VJ, Pratt R, Gibbons GH. Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. Drugs 1994; 47(Suppl 4):1-13.
14. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition in diabetic nephropathy. N Engl J Med 1993;323:1456-1462.
15. Sihm I, Schroeder AP, Aalkjœr C, et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood Press 1995;4:241-248.
16. Fabre J-K, Rivard A, Magrin M, et al. Angiotensin-coverting enzyme inhibition with quinaprilate stimulates angiogenesis in a rabbit model of hindlimb ischemia [abstract]. J Am Coll Cardiol 1988:31(Suppl A):239A.
17. Barenbrock M, Spieker C, Hoeks APG, et al. Effect of lisinopril and metoprolol on arterial distensibility. Hypertension 1994;23(Suppl I):I161-I163.
18. Suraniti S, Berrut G, Marre M, et al. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol 1993; 71:28E-31E.
19. Schmieder RK, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-569.
20. Yusuf S, Sleight P, Poguc J, et al. Effects of an angiotensin-eonverting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.